Skip to main content
Clinical Trials/NCT07328555
NCT07328555Active, not recruitingNot Applicable

Site Randomized Clinical Trial of the Effect of Digital Otoscopy Versus Standard Otoscopy on the Diagnosis and Treatment of Otitis Media in Young Children

Boston Children's Hospital1 site in 1 country36 target enrollmentStarted: March 1, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
36
Locations
1
Primary Endpoint
Change in proportion of visits with any respiratory diagnosis in which otitis media is diagnosed and treated with antibiotics (referred to as the otitis media treatment index - OMTI).

Study Overview

Brief Summary

Randomized controlled trial involving 4 pediatric primary care practices in Massachusetts. Practices will be stratified by their OM diagnosis and treatment rate, with two practices randomly assigned to the intervention arm and two to the control arm.

For practices randomized to the intervention arm, their offices will be equipped with digital otoscopes (Wispr Digital Otoscope, WiscMed) in each exam room in place of traditional otoscopes. Clinicians in intervention practices will attend a two-hour initial training session on the use of digital otoscopy followed by two one-hour follow-up sessions held over a two-month run-in period prior to the study start to review best practices and troubleshoot any difficulties adapting to the new technology.

Upon completion of the run-in training period, a six-month data collection period will begin. The primary outcome will consist of a difference-in-difference analysis comparing the difference in the OM Treatment Index (OMTI) from the baseline period (October 1 through March 31, 2025) to the intervention period (October 1 through March 31, 2026) between the intervention practices and the control practices. The OMTI is a measure of the rate of diagnosis and antibiotic treatment of OM, specifically calculated as the number of cases with an OM diagnosis and systemic antibiotic prescribed divided by the number of visits with a diagnosis of any acute respiratory tract illness.

Secondary outcomes include analogous difference-in-difference comparisons of: 1) overall antibiotic courses prescribed; 2) overall days of antibiotics prescribed; and 3) a balancing measure of the rate of return visits with any acute respiratory tract illness diagnosis within 7 days of an index visit. Additionally, clinicians will be surveyed to assess confidence and satisfaction in diagnosing OM and preference for digital versus traditional otoscopy.

To incentivize participation, practices randomized to the control arm will be loaned digital otoscopes to use for six months at the conclusion of the clinical trial.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • PPOC practices with 4-9 patient exam rooms, willing to commit to using digital otoscopy for 6 months.
  • Not currently using digital otoscopy.
  • Not involved in the network's previous digital otoscopy study

Exclusion Criteria

  • Currently using any digital otoscope

Arms & Interventions

No intervention: Control

No Intervention

No intervention - standard otoscopy to be used

Experimental: Digital Otoscopy

Experimental

Use of the Wispr digital otoscope to diagnose otitis media in place of a traditional visual otoscope

Intervention: Device: Digital Otoscope (Device)

Outcomes

Primary Outcomes

Change in proportion of visits with any respiratory diagnosis in which otitis media is diagnosed and treated with antibiotics (referred to as the otitis media treatment index - OMTI).

Time Frame: 6 months

Difference-in-differences analysis of the change in OMTI from baseline to the intervention period comparing the intervention arm to the control arm using logistic regression with nested random effect at the practice level.

Secondary Outcomes

  • Change in overall antibiotic courses prescribed(6 months)
  • Change in overall prescribed antibiotic days(6 months)
  • Return acute respiratory tract illness visits(Within 7 days of index visit)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jon Hatoun

Director of Data Analytics

Boston Children's Hospital

Study Sites (1)

Loading locations...

Similar Trials